The market for myasthenia gravis treatment was valued at US$ 1.2 billion in 2021 and is anticipated to grow at a CAGR of 7% between 2023 to 2032.
Increasing awareness about rare diseases, rising investment in development of advanced neural therapies, and increasing investment in drug discovery are the key attributes fueling the growth of myasthenia gravis treatment market in future. The pharmaceutical manufacturers are focusing on the development of drugs and therapeutics for application in conjunction with the rapid immunotherapies for effective treatment of myasthenia gravis.
This is anticipated to drive the adoption of drug therapeutics for the treatment of myasthenia gravis during the forecast period. Increasing incidences of myasthenia gravis and increasing investment in biologics are expected to drive the global myasthenia gravis treatment market during the forecast period.
North America contributed the largest share to the global myasthenia gravis treatment market in 2019 and is anticipated to be a dominating geography during the forecast period owing to increasing number of patients with myasthenia gravis, increasing investment in drug discovery, and rising awareness regarding rare diseases.
Availability of robust healthcare infrastructure and early detection & diagnostic of myasthenia gravis is anticipated to bolster growth of myasthenia gravis treatment market in coming years. Europe is expected to contribute a prominent share to the global myasthenia gravis treatment market. The Asia Pacific myasthenia gravis treatment market is anticipated to grow at a steady rate during the forecast period.
The report titled “Myasthenia Gravis Treatment Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global myasthenia gravis treatment market.
Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market. For instance, Novartis AG reported revenues of USD 47,445 million in 2019 and the product segment analysis of the company indicates that Innovative Medicines business segment of the company dominated revenue in 2019.
The global myasthenia gravis treatment market is segmented based on treatment type, end use, and geography. Based on treatment type, the global myasthenia gravis treatment market is segmented into drug treatment, rapid immunotherapies, and thymectomy. The drug treatment method is sub-segmented into cholinesterase inhibitors, chronic immunomodulators, and monoclonal antibodies. The rapid immunotherapies are further sub-segmented into plasmapheresis, and intravenous immunoglobulin (IVLG). Based on end use, the global myasthenia gravis treatment market is segmented into hospitals, clinics, and others. Based on geography, the global myasthenia gravis treatment market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment, and would identify the segment of the company focusing on myasthenia gravis treatment. Further, market share of prominent companies in the global myasthenia gravis treatment market would also be estimated. For instance, Novartis AG operates through two business segments namely Innovative Medicines, and Sandoz. The myasthenia gravis treatment are delivered under Innovative Medicines business segment of the company with revenue contribution of US$ 37,714 million in 2019.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the radial artery compression device companies. The global myasthenia gravis treatment market study would take into consideration the participants engaged throughout the value chain and supply chain of the market, along with their contribution.
Product portfolio would focus on all the products under the myasthenia gravis treatment business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global myasthenia gravis treatment market.
Major players active in the global myasthenia gravis treatment market include Alexion Pharmaceutical Inc., Avadel Pharmaceuticals, PLC. (Flamel Technologies), CSL Behring, Grifols, S.A., Baxter International, Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited and Valeant Pharmaceuticals International, Inc.
Market Segmentation:
By Treatment
- Medication
- Surgery
- Others
By End Use
By Geography:
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- India
- China
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Rest of South America
